An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

Exclusion Criteria

• •Active bacterial, viral, fungal, or parasitic infection.
• •A white blood cell (WBC) counts\<3×10\^9/L, and/or platelet counts\<100×10\^9/L not related to hypersplenism.
• •Uncorrected bleeding disorder.
• •Presence of severe diseases that judged not compatible with the study procedures, such as severe hepatic disease, kidney disease, lung disease, and/or cardiovascular disease.
• •Uncontrolled seizure disorder.
• •Any evidence of severe iron overload that, in the investigator's opinion, warrants exclusion.
• •Prior autologous hematopoietic stem cell transplantation.
• •Prior receipt of gene therapy.